Skylands Capital LLC Increases Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Skylands Capital LLC boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 9.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 550,150 shares of the company's stock after acquiring an additional 45,650 shares during the period. Skylands Capital LLC owned about 0.11% of Elanco Animal Health worth $5,777,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Hedges Asset Management LLC grew its stake in shares of Elanco Animal Health by 4.5% during the first quarter. Hedges Asset Management LLC now owns 115,500 shares of the company's stock worth $1,213,000 after purchasing an additional 5,000 shares in the last quarter. New World Advisors LLC lifted its holdings in Elanco Animal Health by 39.2% during the 1st quarter. New World Advisors LLC now owns 43,000 shares of the company's stock worth $452,000 after buying an additional 12,100 shares during the last quarter. Wealthquest Corp acquired a new position in shares of Elanco Animal Health during the 1st quarter worth about $56,000. Institute for Wealth Management LLC. boosted its position in shares of Elanco Animal Health by 25.9% during the 1st quarter. Institute for Wealth Management LLC. now owns 44,716 shares of the company's stock worth $470,000 after acquiring an additional 9,200 shares in the last quarter. Finally, Rakuten Securities Inc. increased its holdings in shares of Elanco Animal Health by 81.2% in the 1st quarter. Rakuten Securities Inc. now owns 37,275 shares of the company's stock valued at $391,000 after acquiring an additional 16,700 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

NYSE ELAN remained flat at $14.29 on Monday. The company's stock had a trading volume of 3,566,416 shares, compared to its average volume of 5,098,663. The firm has a market capitalization of $7.10 billion, a PE ratio of 15.20, a P/E/G ratio of 2.80 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $15.78. The company's 50-day moving average is $12.39 and its 200-day moving average is $11.50. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. Elanco Animal Health's revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 EPS. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 19th. Finally, William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.